NASDAQ:FTSV

Forty Seven Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$95.51
0.00 (0.00 %)
(As of 04/7/2020)
Add
Compare
Today's Range
$95.51
Now: $95.51
$95.51
50-Day Range
$95.51
MA: $95.51
$95.51
52-Week Range
$5.53
Now: $95.51
$95.51
VolumeN/A
Average Volume1.61 million shs
Market Capitalization$4.60 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.4
Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.
Forty Seven logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FTSV
CUSIPN/A
CIKN/A
Phone650-352-4150
Employees57
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.68 million
Book Value$7.52 per share

Profitability

Net Income$-87,620,000.00

Miscellaneous

Market Cap$4.60 billion
Next Earnings DateN/A
OptionableNot Optionable

Headlines

FORTY SEVEN INC. (4C8.DU)
October 12, 2020 |  in.finance.yahoo.com
Forty Seven Inc. Registered Sha (4C8.SG)
October 10, 2020 |  au.finance.yahoo.com
Gilead Sciences: Debt Fueled Bottom
September 25, 2020 |  seekingalpha.com
FORTY SEVEN INC. (4C8.BE)
August 20, 2020 |  ca.finance.yahoo.com
Gilead completes Forty Seven buy
April 7, 2020 |  seekingalpha.com
Gilead nearing finish line on Forty Seven buy
March 30, 2020 |  seekingalpha.com
6 Stocks To Watch For March 23, 2020
March 23, 2020 |  www.benzinga.com
Forty Seven EPS beats by $0.10
March 20, 2020 |  seekingalpha.com
See More Headlines

MarketRank

Overall MarketRank

1.02 out of 5 stars

Medical Sector

1039th out of 2,021 stocks

Pharmaceutical Preparations Industry

475th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Receive FTSV News and Ratings via Email

Sign-up to receive the latest news and ratings for FTSV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Forty Seven (NASDAQ:FTSV) Frequently Asked Questions

What stocks does MarketBeat like better than Forty Seven?

Wall Street analysts have given Forty Seven a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Forty Seven wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Forty Seven's earnings last quarter?

Forty Seven Inc (NASDAQ:FTSV) released its earnings results on Tuesday, November, 12th. The company reported ($0.38) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.38). The firm had revenue of $15.68 million for the quarter, compared to the consensus estimate of $15.80 million.
View Forty Seven's earnings history
.

Who are Forty Seven's key executives?

Forty Seven's management team includes the following people:
  • Dr. Mark A. McCamish, Pres, CEO & Director (Age 66)
  • Dr. Craig S. Gibbs, Chief Bus. Officer (Age 56)
  • Dr. Chris H. Takimoto M.D., Ph.D., Chief Medical Officer (Age 60)
  • Mr. Mark Chao, Founder & VP of Clinical Devel.
  • Mr. Jens-Peter Volkmer, Founder and VP of Research & Early Devel.

Who are some of Forty Seven's key competitors?

What other stocks do shareholders of Forty Seven own?

When did Forty Seven IPO?

(FTSV) raised $100 million in an IPO on Thursday, June 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers.

What is Forty Seven's stock symbol?

Forty Seven trades on the NASDAQ under the ticker symbol "FTSV."

What is Forty Seven's stock price today?

One share of FTSV stock can currently be purchased for approximately $95.51.

How much money does Forty Seven make?

Forty Seven has a market capitalization of $4.60 billion and generates $15.68 million in revenue each year. The company earns $-87,620,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis.

How many employees does Forty Seven have?

Forty Seven employs 57 workers across the globe.

What is Forty Seven's official website?

The official website for Forty Seven is www.fortyseveninc.com.

Where are Forty Seven's headquarters?

Forty Seven is headquartered at 1490 O`BRIEN DRIVE SUITE A, MENLO PARK CA, 94025.

How can I contact Forty Seven?

Forty Seven's mailing address is 1490 O`BRIEN DRIVE SUITE A, MENLO PARK CA, 94025. The company can be reached via phone at 650-352-4150 or via email at [email protected]


This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.